Related Experiment Video

Updated: Mar 16, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.7K

Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases

Sabrina Fechtner1, David A Fox2, Salahuddin Ahmed1

  • 1Department of Pharmaceutical Sciences, Washington State University College of Pharmacy, Spokane, WA.

Rheumatology (Oxford, England)
|August 24, 2016
PubMed

Insights

Transforming growth factor β activated kinase 1 (TAK1) inhibition offers a promising strategy to reduce chronic inflammation in diseases like rheumatoid arthritis. Targeting TAK1 may overcome limitations of current cytokine-based therapies.

Area of Science:

  • Immunology
  • Molecular Biology
  • Rheumatology

Background:

  • Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) are key in autoinflammatory diseases.
  • Current cytokine-targeting therapies face challenges like drug resistance and limited efficacy.
  • Alternative strategies targeting intracellular signaling molecules are needed to minimize inflammation and tissue injury.

Purpose of the Study:

  • To explore the role of transforming growth factor β activated kinase 1 (TAK1) in inflammatory pathways.
  • To review the therapeutic potential of TAK1 inhibition for chronic inflammatory and rheumatic diseases.
  • To discuss the current development status of TAK1 inhibitors.

Main Methods:

  • Review of scientific literature on TAK1's role in inflammatory signaling.
  • Analysis of TAK1's position in IL-1β, TNF-α, and toll-like receptor pathways.
  • Evaluation of evidence supporting TAK1 inhibition in rheumatic diseases (RA, OA, gout, SS).

Main Results:

  • TAK1 is activated by key inflammatory stimuli including IL-1β, TNF-α, and toll-like receptors.
  • TAK1 acts upstream of critical signaling cascades like MAPKs and the IκB kinase complex.
  • Evidence suggests TAK1 inhibition holds therapeutic potential for chronic inflammatory conditions.

Conclusions:

  • TAK1 is a crucial mediator of inflammatory responses relevant to rheumatic diseases.
  • Targeting TAK1 presents a viable strategy to address limitations of current anti-cytokine therapies.
  • Further development and testing of TAK1 inhibitors in rheumatic diseases are warranted.
Keywords:
Sjögren’s syndromeTAK1goutinflammationinhibitionosteoarthritisrheumatoid arthritis

More Related Videos

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay11:38

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay

Published on: September 14, 2021

3.9K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.6K